Anti-GBM Disease & Goodpasture

The contract between this chapter and the reader.

1. 1. Define anti-GBM disease and the Goodpasture syndrome.
2. 2. Explain the mechanism (anti-collagen-IV antibody).
3. 3. Recognise the pulmonary-renal presentation.
4. 4. Diagnose with anti-GBM antibody and biopsy.
5. 5. Test for ANCA (double-positive disease).
6. 6. Treat urgently with plasma exchange, steroids, and cyclophosphamide.
7. 7. Understand the central role of plasma exchange.
8. 8. Recognise the prognosis and the treatment window.
9. 9. Distinguish anti-GBM from ANCA disease.

A sixty-second reading. Each bullet stands alone.

• Anti-GBM disease is caused by antibody to the alpha-3 chain of type IV collagen in basement membranes.
• It causes a rapidly progressive, crescentic glomerulonephritis, often with pulmonary hemorrhage.
• The Goodpasture syndrome is the combination of glomerulonephritis and pulmonary hemorrhage.
• It presents acutely and severely, frequently dialysis-dependent at presentation.
• Pulmonary hemorrhage is life-threatening, especially in smokers.
• Diagnosis is by the anti-GBM antibody and biopsy showing linear IgG along the GBM.
• About a third of patients are also ANCA-positive (double-positive disease).
• Treatment is urgent: plasma exchange plus corticosteroids and cyclophosphamide.
• Plasma exchange is central, removing the pathogenic antibody.
• Treatment must start early, before crescents become irreversible.
• Renal recovery is unlikely if dialysis-dependent with extensive crescents at presentation.
• The disease is usually monophasic and does not relapse once the antibody clears.
• Transplantation is deferred until the antibody has been negative for months.

The medical core. An expert should agree anti-GBM disease is fully covered here.

Why it matters at the bedside

Anti-GBM disease is nephrology at its most time-pressured. A single autoantibody can destroy both kidneys and fill the lungs with blood within days — and the window to save the kidney closes almost as fast as it opens. Recognise the linear staining, test for the antibody (and for ANCA), and start the triple at once: this is a disease where hours decide outcomes.

What it is and the Goodpasture syndrome

• Anti-GBM disease is an autoantibody disease against the alpha-3 chain of type IV collagen — the Goodpasture antigen — found in both the glomerular and alveolar basement membranes. In the kidney it causes a necrotizing crescentic glomerulonephritis (rapidly progressive GN); in the lung it causes haemorrhage. The Goodpasture syndrome is the combination of glomerulonephritis and pulmonary haemorrhage, though anti-GBM disease can also be renal-limited.

The mechanism

• The Goodpasture antigen is normally hidden within the collagen IV network; certain triggers — smoking, infection, inhaled toxins — expose it, particularly in the lung, and an autoantibody forms against it. The antibody binds smoothly along the basement membrane (the linear immunofluorescence of the first chapter), fixing complement and recruiting a severe, crescentic injury. The same antigen in the alveoli explains the pulmonary haemorrhage, and why smokers are especially affected.

The pulmonary-renal presentation

• It presents acutely and severely. The renal disease is a rapidly progressive glomerulonephritis, often with oliguria or anuria and frequently dialysis-dependent by the time of presentation. The pulmonary disease — haemoptysis, dyspnea, diffuse infiltrates — is life-threatening, especially in smokers. The combination is the classic pulmonary-renal syndrome, with a bimodal pattern: younger patients (often men) tend to present with lung involvement, older patients with renal-limited disease.

Diagnosis: antibody and biopsy

• Diagnosis rests on the anti-GBM antibody (serology, which confirms it) and the biopsy, which shows the diagnostic linear deposition of IgG along the glomerular basement membrane on immunofluorescence, with a necrotizing crescentic glomerulonephritis on light microscopy. Both should be obtained urgently, because the diagnosis must be made before the crescents fibrose.

Double-positive disease

• Crucially, about a third of anti-GBM patients are also ANCA-positive — double-positive disease — so every anti-GBM patient is tested for ANCA (and vice versa, the rule from the ANCA chapter). Double-positive disease behaves worse and, unlike pure anti-GBM, can relapse like ANCA vasculitis, so it is managed with that combined behaviour in mind.

Urgent treatment: the triple

• Treatment is a three-part regimen, started urgently: plasma exchange, corticosteroids, and cyclophosphamide. The urgency is the point — every day of delay loses nephrons to fibrosis — so treatment begins on a compelling clinical and serologic picture rather than waiting, and the lung is treated aggressively because pulmonary haemorrhage is immediately life-threatening.

The central role of plasma exchange

• Here, unlike in ANCA vasculitis, plasma exchange is central rather than selective: anti-GBM disease is the archetypal indication, because removing the circulating pathogenic antibody directly addresses the mechanism. It is used in essentially all cases with pulmonary haemorrhage or a potentially salvageable kidney, alongside the immunosuppression that stops further antibody production.

Prognosis and the window

• Prognosis is governed by how early treatment starts. A kidney that is already dialysis-dependent with extensive crescents at presentation rarely recovers — the damage is fixed — though the lung is still treated to save life; a kidney caught early can be salvaged. The encouraging counterpoint is that the disease is usually monophasic: once the antibody clears, it does not relapse (the exception being double-positive disease), so long-term immunosuppression is not needed, and transplantation — deferred until the antibody has been negative for months — does well.

Anti-GBM versus ANCA

• The crescentic-GN trio is best held in contrast. Anti-GBM is linear-IgG, monophasic, with plasma exchange central and poor renal salvage if treated late. ANCA is pauci-immune, relapsing, with plasma exchange selective and often better late salvage. Immune-complex crescentic GN is granular. And double-positive disease carries the features of both — the severity and antibody of anti-GBM with the relapsing course of ANCA — which is why testing for both is mandatory.

Five fully-built tables.

Table A — The disease at a glance

Table B — Presentation

Table C — Diagnosis

Table D — Treatment (the triple)

Table E — Anti-GBM versus ANCA

Visualise & Map

Causal chains, each ending in a named action.

Chain 1 — The autoantibody

Antibody to collagen IV alpha-3 → linear deposition along the GBM → severe necrotizing crescentic GN → ACTION: remove the antibody (plasma exchange) and immunosuppress.

Chain 2 — Two membranes, one antigen

The same antigen sits in the alveolar membrane → antibody binds the lung (exposed by smoking) → life-threatening pulmonary haemorrhage → ACTION: treat urgently, plasma exchange central.

Chain 3 — The closing window

Crescents fibrose quickly → the salvage window is short → late presentation (dialysis-dependent) means fixed renal damage → ACTION: treat early; if clearly irreversible, treat the lung and weigh renal therapy.

Chain 4 — The single wave

Once the antibody is cleared → no ongoing driver → the disease is monophasic and does not relapse → ACTION: avoid indefinite immunosuppression; transplant once antibody-negative.

Chain 5 — Both at once

ANCA can coexist with anti-GBM → double-positive disease → worse outcomes and a relapsing course → ACTION: test ANCA in every anti-GBM patient and manage as both.

Numbered rules. These numbers are the cross-reference handle for the cases and flowcharts.

Clinical Reasoning

Five cases. Each stops you at a decision before it answers it.

Every mechanism from Level 3 earns a bedside consequence and an action.

Exhaustive. Every rule in the chapter is here.

Safety & Evidence

Panel A — Red flags

Panel B — NEVER DO

Anti-patterns clinicians fall into. Each becomes a Level 22 distractor.

The grade reflects strength of evidence, not importance.

Patient Decisions

Outcomes as natural frequencies. Figures are representative; the direction of effect is given where precise numbers are uncertain.

Apply & Test

Copy-paste chart notes that map to the real decisions in this chapter.

Template 1 — Anti-GBM diagnosis note

• Presentation: RPGN; pulmonary haemorrhage; oligoanuria / dialysis-dependent ___.
• Anti-GBM antibody: positive; titre ___.
• ANCA: tested (double-positive?) ___.
• Biopsy: linear IgG; necrotizing crescentic GN; crescent burden ___.
• Renal salvageability (early vs dialysis-dependent + extensive crescents): ___.

Template 2 — Urgent treatment plan note

• Triple started urgently: plasma exchange + corticosteroids + cyclophosphamide ___.
• Plasma exchange (pulmonary haemorrhage / salvageable kidney): ___.
• Pulmonary haemorrhage: managed; smoking cessation ___.
• Antibody clearance / monophasic course; relapse watch if double-positive ___.
• Transplant deferred until antibody negative for months: ___.

Pre-rounds compression. Rules only.

Active recall. At least one card per objective.

Micro-teaching for rounds. Two scenarios, five steps each.

Nine items, each anchored in this chapter. At least one per objective.